The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters

Uterine fibroids, also known as myomas, are one of the most frequently observed hormonal-dependent benign tumours of the female genital tract. Their prevalence is estimated to be up to 68% among reproductive age women and they can be responsible for invalidating symptoms, such as abnormal uterine bleeding, pelvic pain, infertility and/or symptoms derived from pelvic compression. The treatment of uterine fibroids depends on their size, number, location and the patient's wish to preserve her uterus. It includes hormonal therapy (progestin-only, agonists or antagonists of the gonadotropin-releasing hormone [GnRH]), surgery (myomectomy or hysterectomy), thermal ablation through radiofrequencies or focalised ultrasounds and radiological uterine artery embolization.

Endometriosis is a chronic disease affecting 10% of reproductive age women. It can be responsible for symptoms such as pelvic pain in the form of dysmenorrhea, chronic pain and dyspareunia, as well as infertility. These symptoms depend on the proliferation of endometriotic lesions which, in turn, occurs mainly under the influence of oestradiol. Because of this physio-pathological mechanism, international guidelines recommend the use of medical treatment in order to lower oestradiol synthesis by inhibiting ovulation. Similarly to uterine fibroids, medical treatment includes oestro-progestin or progestin-only pill, agonists and antagonists of the GnRH.

As of February 2023, Swissmedic has approved the combined hormonal therapy known as Ryeqo® for treatment of abnormal uterine bleeding associated with uterine fibroids. Ryeqo® consists of an oral treatment, available as a pill, which contains 40 mg of the GnRH antagonist Relugolix, combined with 1 mg of oestradiol and a progestin, such as norethisterone acetate, at the dose of 0.5 mg. As the GnRH antagonist suppresses the hypothalamus-pituitary-gonadal axis, its combination with add -back hormonal replacement therapy maintains a low but constant oestradiol level, which minimizes vasomotor symptoms and long-term consequences of oestrogen deficiency, such as bone mineral density loss. Recent studies have assessed the efficacy of Ryeqo® for both abnormal uterine bleeding associated with uterine fibroids and endometriosis-associated pain, leading to the recent approval, as of April 2025, of Ryeqo® not only for uterine fibroids but also for treatment of moderate to severe pain among women with endometriosis in Switzerland.

While the efficacy of Ryeqo® in the management of abnormal uterine bleeding associated with uterine fibroids and pelvic pain due to endometriosis has been established, the drug's impact on hemostasis parameters has yet to be determined. This particular aspect merits attention, considering that the incidence of venous thromboembolism (VTE) varies based on age and is estimated to be 1-2/10,000 women-year between 15 and 34 years of age, and 3-5/10,000 women-year between 35 and 44 years of age. The clinical presentation varies between pulmonary embolism, which is potentially fatal, and veinous thrombosis. VTE has relevant short- and long-term morbidity, with a risk of 2-4% of chronic pulmonary hypertension and 3-10% of moderate-to-severe post-thrombotic syndrome.

VTE is the main, potentially fatal, deleterious effect of oestrogen-containing hormonal treatment, such as combined oral contraceptives (COC). Several epidemiological studies have found a 3-6 increase in the risk of VTE among women on COC. The thrombogenic risk can be assessed by measuring specific blood biomarkers, which are known to be correlated to the thrombogenic phenotype and allow an overview of the VTE risk prior to conducting large population-scale studies directly measuring the adverse event's prevalence. For contraceptive and hormone therapy, sensitivity of thrombin generation to the activated protein C (APC) pathway is a validated surrogate biomarker for estrogen-related VTE risk. Dosage of sex hormone-binding globulin (SHBG) also allow to assess VTE risk among COC users. These two biomarkers are used to assess VTE risk of new COC preparations.

Although no studies have yet specifically assessed the thrombogenic risk associated with the administration of Ryeqo®, a pooled analysis based on five prospective cohort studies concluded that oestradiol alone was associated with a decreased risk of VTE compared to ethynyl-oestradiol, while norethindrone acetate was associated with a risk comparable to that of oestrogens and progestins. The two active compounds combined with a GnRH antagonist, however, have not been studied for what concerns their impact on VTE risk. Based on the available literature, it is reasonable to presume that Ryeqo®'s administration has an impact on coagulation markers, thus explaining why the treatment is currently contraindicated in women who are experiencing, or have in the past experienced, venous or arterial thromboembolic events or who are at increased risk of such events due to their personal medical history. For this same reason, women are advised to suspend treatment with Ryeqo® in case the risk of VTE may be temporarily increased.

The aim of this study is to document the effects of Ryeqo® on hemostasis parameters in order to estimate the risk of VTE associated with its employ. An improved understanding of the VTE risk associated with Ryeqo® will allow to adapt hormonal treatment based on each woman's personal risk profile.

Inclusion criteria

• Women consulting at the DFEA of the HUG, who are prescribed Ryeqo® for a qualified medical condition
• Age ≥ 18 years

Exclusion criteria

• Unable to speak and/or read French
• Having used either an oestro-progestin pill (oral, patch or vaginal ring) or oral estrogens in the past 3 months, or DMPA or nomegestrol acetate
• Women not having given their consent to participate in the study